A speedy FDA offers lightning review and quick OK for the latest PD-1 from Regeneron and Sanofi
The FDA really didn’t need until the end of October to decide on whether it wanted to approve cemiplimab, the world’s 6th PD-1/L1 from Sanofi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
